Mark McCamish Net Worth
The estimated Net Worth of Mark Anthony Mc Camish is at least $2.18 Million dollars as of 20 May 2019. Mark Camish owns over 16,500 units of Forty Seven stock worth over $422,288 and over the last 13 years he sold FTSV stock worth over $0. In addition, he makes $1,752,790 as President, Chief Executive Officer, and Director at Forty Seven.
Mark McCamish FTSV stock SEC Form 4 insider trading
Mark has made over 7 trades of the Forty Seven stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 16,500 units of FTSV stock worth $80,520 on 20 May 2019.
The largest trade he’s ever made was exercising 51,687 units of Forty Seven stock on 25 January 2019 worth over $252,233. On average, Mark trades about 13,608 units every 13 days since 2007. As of 20 May 2019 he still owns at least 62,010 units of Forty Seven stock.
You can see the complete history of Mark Camish stock trades at the bottom of the page.
Mark McCamish biography
Dr. Mark Anthony McCamish is President, Chief Executive Officer, Director of the Company. From July 2009 to April 2017, Dr. McCamish served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish received both a B.A. in Physical Education and an M.A. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Nutritional Sciences from the Pennsylvania State University and an M.D. from the University of California at Los Angeles. McCamish’s experience in the industry, his role as our President and Chief Executive Officer and his knowledge of our company enable him to make valuable contributions to our Board of Directors.
What is the salary of Mark McCamish?
As the President, Chief Executive Officer, and Director of Forty Seven, the total compensation of Mark McCamish at Forty Seven is $1,752,790. There are no executives at Forty Seven getting paid more.
How old is Mark McCamish?
Mark McCamish is 67, he’s been the President, Chief Executive Officer, and Director of Forty Seven since 2017. There are 2 older and 7 younger executives at Forty Seven. The oldest executive at Forty Seven, Inc. is Irving Weissman, 79, who is the Independent Director.
What’s Mark McCamish’s mailing address?
Mark’s mailing address filed with the SEC is C/O PDL BIOPHARMA, INC., 34801 CAMPUS DRIVE, FREMONT, CA, 94555.
Insider trading at Forty Seven
Over the last few years, insiders at Forty Seven have traded over $4,118,522 worth of Forty Seven stock and bought 2,621,245 units worth $41,666,515 . The most active insider traders include Tench Coxe, Michael L Speiser, and Jeffrey W Bird. On average, Forty Seven executives and independent directors trade stock every 7 days with the average trade being worth of $569,591. The most recent stock trade was executed by Mark Anthony Mc Camish on 20 May 2019, trading 16,500 units of FTSV stock currently worth $80,520.
What does Forty Seven do?
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
What does Forty Seven’s logo look like?
Complete history of Mark Camish stock trades at PDL BioPharma and Forty Seven
Forty Seven executives and stock owners
Forty Seven executives and other stock owners filed with the SEC include:
- Mark McCamish, President, Chief Executive Officer, Director
- Ann Rhoads, Chief Financial Officer
- Chris Takimoto, Chief Medical Officer
- Ian Clark, Independent Director
- Craig Gibbs, Chief Business Officer
- Kristine Ball, Independent Director
- Jeffrey Bird, Lead Independent Director
- Dennis Henner, Independent Director
- Ravindra Majeti, Independent Director
- Irving Weissman, Independent Director
- Samuel J Iii Pullara,
- Harbor Master Investors (Ca…, 10% owner
- Michael L Speiser, 10% owner
- Stefan A Dyckerhoff,
- Venture Partners X, L.P.Lig…,
- Hill Ventures Sutter,
- Peter Nieh, 10% owner
- Christopher J Schaepe, Director
- Tench Coxe, 10% owner
- Dennis Henner, Director
- James N White, 10% owner
- Venture Partners Select Ii,…,
- Ravi Mhatre, 10% owner